Bolt Biotherapeutics Balance Sheet Health

Financial Health criteria checks 4/6

Bolt Biotherapeutics has a total shareholder equity of $72.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $109.3M and $37.3M respectively.

Key information

Debt to equity ratio

US$0

Debt

Interest coverage ratio	n/a
Cash	US$53.80m
Equity	US$72.03m
Total liabilities	US$37.30m
Total assets	US$109.33m

Recent financial health updates

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Nov 30

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Mar 15

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

May 13

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Dec 01

Recent updates

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Nov 30

Little Excitement Around Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Revenues As Shares Take 29% Pounding

May 21

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Mar 15

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

May 13

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Dec 01

Bolt Biotherapeutics: A Promised Follow Up

Aug 26

Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M

Aug 10

Financial Position Analysis

Short Term Liabilities: BOLT's short term assets ($57.1M) exceed its short term liabilities ($18.1M).

Long Term Liabilities: BOLT's short term assets ($57.1M) exceed its long term liabilities ($19.2M).

Debt to Equity History and Analysis

Debt Level: BOLT is debt free.

Reducing Debt: BOLT has no debt compared to 5 years ago when its debt to equity ratio was 19.7%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BOLT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BOLT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 16.5% each year

Discover healthy companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 04:12
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bolt Biotherapeutics, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Michael Schmidt	Guggenheim Securities, LLC
Edward White	H.C. Wainwright & Co.
Soumit Roy	JonesTrading Institutional Services, LLC

Bolt Biotherapeutics Balance Sheet Health

Financial Health criteria checks 4/6

Key information

Recent financial health updates

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Bolt Biotherapeutics Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Requirement under Nasdaq Listing Rule 5450(a)(1)

Bolt Biotherapeutics Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Requirement under Nasdaq Listing Rule 5450(a)(1)

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Recent updates

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

High number of new directors

Bolt Biotherapeutics, Inc. Announces Changes to Its Board of Directors

Consensus EPS estimates fall by 13%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bolt Biotherapeutics Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Requirement under Nasdaq Listing Rule 5450(a)(1)

Bolt Biotherapeutics Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Requirement under Nasdaq Listing Rule 5450(a)(1)

Pomerantz Law Firm Announces the Filing of A Class Action Against Bolt Biotherapeutics, Inc. and Certain Officers - BOLT

High number of new directors

Little Excitement Around Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Revenues As Shares Take 29% Pounding

Consensus revenue estimates decrease by 12%, EPS upgraded

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bolt Biotherapeutics, Inc., Annual General Meeting, Jun 12, 2024

Consensus revenue estimates increase by 44%, EPS downgraded

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Price target increased by 9.4% to US$5.25

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating Bdc-1001 in Patients with Her2-Positive Breast Cancer Previously Treated with Enhertu

Consensus revenue estimates increase by 21%

Bolt Biotherapeutics, Inc. Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

Price target decreased by 7.7% to US$4.80

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Bolt Biotherapeutics, Inc. Appoints Laura Berner to Board of Directors

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$6.40

Bolt Biotherapeutics: A Promised Follow Up

Consensus revenue estimates increase by 36%

Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M

We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Bolt Biotherapeutics, Inc.(NasdaqGS:BOLT) dropped from Russell 2500 Index

Price target decreased to US$11.50

High number of new directors

We're Not Very Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Bolt Biotherapeutics, Inc. Announces Resignation of David Dornan as Chief Scientific Officer, Effective from March 11, 2022

Price target decreased to US$13.67

Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors

Less than half of directors are independent

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Can Afford To Drive Business Growth

Consensus revenue estimates fall to US$1.00m

Bolt Biotherapeutics: Pioneering A New Class Of Immunotherapies

We're Hopeful That Bolt Biotherapeutics (NASDAQ:BOLT) Will Use Its Cash Wisely

Bolt Biotherapeutics, Inc.(NasdaqGS:BOLT) dropped from Russell 3000E Growth Index

Bolt Biotherapeutics, Inc. announced that it has received $15 million in funding from Genmab A/S

Bolt Biotherapeutics, Inc. Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021

Bolt Biotherapeutics, Inc. announced that it expects to receive $15 million in funding from Genmab A/S

Full year 2020 earnings released: US$28.89 loss per share (vs US$15.29 loss in FY 2019)

Bolt Biotherapeutics, Inc. has completed an IPO in the amount of $230 million.

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Cash Runway Analysis

Discover healthy companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources